Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : Pfizer sees robust COVID-19 vaccine demand for years, $26 bln in 2021 sales

05/04/2021 | 06:52am EDT
Pfizer logo in Manhattan, New York

May 4 (Reuters) - Pfizer Inc on Tuesday raised its forecast for 2021 COVID-19 vaccine sales by more than 70% to $26 billion and said demand from governments around the world fighting to halt the pandemic could contribute to its growth for years to come.

The company said it expects to file for full U.S. approval of the vaccine in May for people over the age of 16, as it is now only authorized for emergency use. It also expects to hear soon from U.S. regulators on expansion of the vaccine's emergency use authorization (EUA) for children ages 12-15.

Revenue from the vaccine - developed with German partner BioNTech SE - is expected to account for more than one third of Pfizer's sales this year.

The forecast is based on contracts to deliver 1.6 billion vaccine doses this year. The company expects to sign more deals for this year and is in supply talks with several countries for 2022 and beyond.

"Based on what we've seen, we believe that a durable demand for our COVID-19 vaccine – similar to that of the flu vaccines – is a likely outcome," Chief Executive Albert Bourla said.

The two-shot vaccine was Pfizer's top-selling product in the first quarter. Expenses and profit from the vaccine are split 50-50 between Pfizer and BioNTech.

Given persistent infections globally and ongoing discussions with governments, Mizuho analyst Vamil Divan said the 2021 forecast could increase further and spill over to future years.

Daily vaccination rates for adults in the United States are off more than 25% since hitting a peak in mid-April. Authorization in children would expand the vaccine-eligible population by millions of people.

Pfizer said it expects to have safety and efficacy data for children ages 2-to-11 in September, when it plans to ask for further expansion of the EUA for that age group.

The company has also filed new data with U.S. regulators that would allow the vaccine to be stored at standard refrigerator temperatures for up to four weeks, up from five days currently.

Pfizer and BioNTech aim to produce up to 2.5 billion COVID-19 vaccine doses this year, 900 million of which are not yet included in the New York-based drugmaker's sales forecast.

If Pfizer sells that number of doses at similar prices, the vaccine's sales in 2021 could be more than 50% above the projected $26 billion.

Moderna Inc has forecast $18.4 billion in 2021 sales of its similar COVID-19 vaccine.

Pfizer expects to profit from the vaccine, while some drugmakers including Johnson & Johnson have said their vaccine will be sold on a not-for-profit basis until the end of the pandemic.

Pfizer aims to manufacture at least 3 billion doses of the vaccine next year. It also expects to have safety and immunogenicity data from a third booster dose of the vaccine in July.

Pfizer and BioNTech have published data showing impressive durability for their vaccine at least six months after vaccination. Still, Bourla said he believes regular boosters will be needed to maintain high levels of immunity, and governments around the world have started signing deals for the shots.

The COVID-19 vaccine generated $3.5 billion in revenue in the first quarter, exceeding analysts' estimates of $3.28 billion, according to Refinitiv data.

Total revenue for the quarter of $14.6 billion, topped analysts' forecasts of $13.5 billion.

It plans to boost R&D spending to fuel drug discovery using the messenger RNA technology in the COVID-19 vaccine. The company is developing two flu vaccines that are expected to enter clinical trials in the third quarter.

Pfizer shares were down slightly in afternoon trading.

(Reporting by Manas Mishra in Bengaluru and Michael Erman in Maplewood, N.J; Editing by Arun Koyyur and Bill Berkrot)


© Reuters 2021
All news about MODERNA, INC.
05/10First Covid-19 Vaccine Cleared for U.S. Adolescents -- 2nd Update
DJ
05/10Provinces look to mix COVID-19 vaccines in light of changing supply
AQ
05/10First Covid-19 Vaccine Cleared for U.S. Adolescents -- Update
DJ
05/10KIDS AND THE COVID-19 VACCINE  : Is it Safe and When Can They Get It?
DJ
05/10FDA Authorizes Pfizer-BioNTech Covid-19 Vaccine for 12- to 15-Year-Olds
DJ
05/10MODERNA  : U.S. administers 261.6 mln doses of COVID-19 vaccines - CDC
RE
05/10MODERNA  : U.S. CDC Says Administered 261,599,381 Doses Of COVID-19 Vaccine As O..
RE
05/10ASTRAZENECA  : Europe dares to reopen as 200 millionth vaccine dose delivered
RE
05/10INOVIO PHARMACEUTICALS  : says COVID-19 vaccine candidate safe, effective in mid..
RE
05/10GAVI in talks with China's Sinopharm, other vaccine makers for COVAX doses
RE
More news
Financials (USD)
Sales 2021 18 212 M - -
Net income 2021 10 097 M - -
Net cash 2021 12 094 M - -
P/E ratio 2021 6,55x
Yield 2021 -
Capitalization 63 662 M 63 662 M -
EV / Sales 2021 2,83x
EV / Sales 2022 2,79x
Nbr of Employees 1 300
Free-Float 88,7%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 166,20 $
Last Close Price 158,55 $
Spread / Highest target 45,7%
Spread / Average Target 4,82%
Spread / Lowest Target -47,7%
EPS Revisions
Managers and Directors
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.56.17%65 346
LONZA GROUP AG1.51%47 533
IQVIA HOLDINGS INC.29.20%44 923
CELLTRION, INC.-25.77%32 687
SEAGEN INC.-22.39%25 314
CUREVAC N.V.30.49%21 497